Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis;Revisión sistemática y metaanálisis de la eficacia y la seguridad de leflunomida y metotrexato en el tratamiento de la artritis reumatoide

Reumatologia Clinica

Volumn 15, Issue 3, 2019, Pages 133-139

  Alfaro Lara, Roberto ^a   Espinosa Ortega, Hector Fabricio ^a   Arce Salinas, César Alejandro ^a  

^a PEMEX   (Mexico)

Author keywords

Leflunomide; Meta analysis; Methotrexate; Rheumatoid arthritis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; LEFLUNOMIDE; METHOTREXATE; ANTIRHEUMATIC AGENT; GAMMA GLUTAMYLTRANSFERASE; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CLINICAL ASSESSMENT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GASTROINTESTINAL INFECTION; GASTROINTESTINAL SYMPTOM; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX SCORE; HUMAN; INCIDENCE; JOINT SWELLING; META ANALYSIS; PROTEIN BLOOD LEVEL; QUALITY CONTROL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; DISABILITY; GASTROINTESTINAL DISEASE; TOXIC HEPATITIS;

ALANINE TRANSAMINASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ASPARTATE AMINOTRANSFERASES; C-REACTIVE PROTEIN; CHEMICAL AND DRUG INDUCED LIVER INJURY; CLINICAL TRIALS AS TOPIC; DISABILITY EVALUATION; DRUG THERAPY, COMBINATION; GAMMA-GLUTAMYLTRANSFERASE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEFLUNOMIDE; METHOTREXATE; TREATMENT OUTCOME;

EID: 85028550322     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2017.07.020     Document Type: Article

References (40)

1. Peláez-Ballestas, I., Sanin, L.H., Moreno-Montoya, J., Alvarez-Nemegyei, J., Burgos-Vargas, R., Garza-Elizondo, M., et al. Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumatol Suppl 86 (2011), 3–8.
2. Ollier, W.E.R., Harrison, B., Symmons, D., What is the natural history of rheumatoid arthritis?. Best Pract Res Clin Rheumatol 15 (2001), 27–48.
3. Furneri, G., Mantovani, L.G., Belisari, A., Mosca, M., Cristiani, M., Bellelli, S., et al. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 73 (2012), S72–S84.
4. Lard, L.R., Visser, H., Speyer, I., vander Horst-Bruinsma, I., Zwinderman, A.H., Breedveld, F.C., et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 111 (2001), 446–451.
5. Singh, J.A., Furst, D.E., Bharat, A., Curtis, J.R., Kavanaugh, A.F., Kremer, J.M., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64 (2012), 625–629.
6. Smolen, J., Landewé, R., Breedveld, F., Dougados, M., Emery, P., Gaujoux-Viala, C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs. Ann Rheum Dis 69 (2010), 964–975.
7. Cardiel, M.H., Díaz-Borjón, A., Vázquez del Mercado-Espinosa, M., Gámez-Nava, J.I., Barile-Fabris, L., Pacheco-Tena, C., et al. Update of the Mexican College of Rheumatology guidelines for the pharmacologic treatment of rheumatoid arthritis. Reumatol Clin 10 (2014), 227–240.
8. Pincus, T., Yacizi, Y., Sokka, T., Aletaha, D., Smolen, J.S., Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 21:Suppl. 31 (2003), S179–S185.
9. Braun, J., Kästner, P., Flaxenberg, P., Währiwsch, J., Hanke, P., Demary, W., et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum 58 (2008), 73–81.
10. Pincus, T., Gibson, K.A., Castrejón, I., Update on methotrexate as the anchor drug for rheumatoid arthritis. Bull Hosp Jt Dis 71:Suppl. 1 (2013), S9–S19.
11. Hoekstra, M., van Ede, A.E., Haagsma, C.J., van derLaar, M.A., Huizinga, T.W., Kruijsen, M.W., et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 62 (2003), 423–426.
12. Kinder, A.J., Hassell, A.B., Brand, J., Brownfield, A., Grove, M., Shadforth, M.F., The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse reactions. Rheumatology (Oxford) 44 (2005), 61–66.
13. Salliot, C., van der Heijde, D., Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68 (2009), 1100–1104.
14. Grove, M.L., Hassell, A.B., Hay, E.M., Shadforth, M.F., Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. QJM 94 (2001), 309–319.
15. Davis, J.M., Matteson, E.L., My treatment approach to rheumatoid arthritis. Mayo Clin Proc 87 (2012), 659–673.
16. Dayer, J.M., Cutolo, M., Is there a rationale to using leflunomide in early rheumatoid arthritis?. Clin Exp Rheumatol 23 (2005), 404–412.
17. Behrens, F., Koehm, M., Burkhardt, H., Update 2011: leflunomide in rheumatoid arthritis – strengths and weaknesses. Curr Opin Rheumatol 23 (2011), 282–287.
18. Singer, O., Gibofsky, A., Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011?. Curr Opin Rheumatol 23 (2011), 288–292.
19. Chambers, C.D., Johnson, D.L., Robinson, L.K., Braddock, S.R., Xu, R., López-Jiménez, J., et al. Birth outcomes in women have taken leflunomide during pregnancy. Arthritis Rheum 62 (2010), 1494–1503.
20. Felson, D.T., Anderson, J.J., Boers, M., Bombardier, C., Chernoff, M., Fried, B., et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 36 (1993), 729–740.
21. Aletaha, D., Machold, K.P., Nell, V.P.K., Smolen, J.S., The perception of rheumatoid arthritis core set measures by rheumatologist. Results of a survey. Rheumatology (Oxford) 45 (2006), 1133–1139.
22. Higgins, J.P.T., Green, S., Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. 2011, The Cochrane Collaboration Available from: https://www.cochrane-handbook.org [updated March 2011].
23. Jaimes-Hernández, J., Meléndez-Mercado, C.I., Eficacia de leflunomida 100 mg semanales comparado con dosis bajas de metotrexate en pacientes con artritis reumatoide activa. Estudio clínico doble ciego aleatorizado. Reumatol Clin 8 (2012), 243–249.
24. Ishaq, M., Muhammad, J.S., Hameed, K., Mirza, A.I., Leflunomide or methotrexate? Comparison of clinical efficacy and safety in low socio-economic rheumatoid arthritis patients. Mod Rheumatol 21 (2011), 375–380.
25. Emery, P., Breedveld, F.C., Lemmel, E.M., Kaltwasser, J.P., Dawes, P.T., Gömör, B., et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 39 (2000), 655–665.
26. Cohen, S., Cannon, G.W., Schiff, M., Weaver, A., Fox, R., Olsen, N., et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 44 (2001), 1984–1992.
27. Strand, V., Cohen, S., Schiff, M., Weaver, A., Fleischmann, R., Cannon, G., et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 159 (1999), 2542–2550.
28. Moreland, L.W., Fleischmann, R.M., Strand, V., Efficacy of leflunomide vs placebo vs methotrexate in early and late rheumatoid arthritis. Arthritis Rheum, 41, 1998, S155.
29. Smolen, J.S., Kalden, J.R., Scott, D.L., Rozman, B., Kvien, T.K., Larsen, A., et al. Efficacy and safety of leflunomide compared with placebo and sulfasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 353 (1999), 259–266.
30. Strand, V., Tugwell, P., Bombardier, C., Maetzel, A., Crawford, B., Dorrier, C., et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum 42 (1999), 1870–1878.
31. Sharp, J.T., Strand, V., Leung, H., Hurley, F., Loew-Friedrich, I., Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 43 (2000), 495–505.
32. Tugwell, P., Wells, G., Strand, V., Maetzel, A., Bombardier, C., Crawford, B., et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum 43 (2000), 506–514.
33. Smolen, J.S., Landewé, R., Breedveld, F.C., Buch, M., Burmester, G., Dougados, M., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73 (2014), 492–509.
34. Ringold, S., Singer, N.G., Measures of disease activity in rheumatoid arthritis: a clinician's guide. Curr Rheumatol Rev 4 (2008), 259–265.
35. Pincus, T., The American College of Rheumatology (ACR) core set and derivative “patient only” indices to assess rheumatoid arthritis. Clin Exp Rheumatol 23:Suppl. 39 (2005), S109–S113.
36. Verhoeven, A.C., Boers, M., van der Linden, S., Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis. Ann Rheum Dis 59 (2000), 966–974.
37. Grijalva, C., Chung, C.P., Arbogast, P.G., Stein, C.M., Mitchel, E.F., Griffin, M.R., Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 45 (2007), S66–S76.
38. Osiri, M., Shea, B., Robinson, V., Suárez-Almazor, M., Strand, V., Tugwell, P., Wells, G., Leflunomide for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. J Rheumatol 30 (2003), 1182–1190.
39. Osiri, M., Shea, B., Robinson, V., Suarez-Almazor, M., Strand, V., Tugwell, P., Wells, G., Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev, 1, 2003, CD002047.
40. Scott, D.L., Smolen, J.S., Kalden, J.R., van den Putte, L.B.A., Larsen, A., Kvien, T.K., et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 60 (2001), 913–923.